(Please click on logo to access DealRoom financing)
By now, tech investors at Stockhouse will know the name Theralase Technologies Inc. (TSX: V.TLT, OTCQ: TLTFF, Forum). Who can forget a company that uses “super-pulsed” laser technology and works with some of the leading athletes and sports entities in North America (in its Therapeutic Laser Division)?
However, where TLT has really been turning heads in the tech sector and investment community is with its quest for a cure for cancer. Stockhouse originally introduced our audience to Theralase in a full-length feature article from April 13, 2017.
Cancer has traditionally been fought with brute-force methods: chemotherapy, radiation therapy and surgery, with limited success. Theralase’s research centers on a method for eliminating cancer cells that is as subtle and ingenious as it is benign.
Using its proprietary “Trojan Horse” (TLD-1433), TLT infiltrates cancer cells with this seemingly harmless photo-dynamic compound (PDC). Once inside, cool laser light transforms TLD-1433 into a cancer-killer – from within. It’s a mode of cancer treatment that causes virtually zero damage to surrounding tissue.
Theralase is about to take this exciting research to a Phase II clinical study for non-muscle invasive bladder cancer (NMIBC). This means not only research on human patients. This is research that has now progressed beyond “safety and tolerance” testing (Phase I) and is moving to the “efficacy” stage of the pharmaceutical clinical study model – clinical proof that the treatment is successful.
Such clinical studies are still speculative, however. More risk-averse investors may be leery of investing in a junior tech company, despite the spectacular economic potential of success in treating even one form of cancer (bladder cancer is a multi-billion dollar market in the U.S. alone).
For such investors, Theralase may have come up with the proverbial “offer too good to refuse”. Enter the Stockhouse DealRoom. Stockhouse is hosting TLT’s latest financing and the terms will be very enticing to investors.
The Company is seeking to raise up to $10 million. Units are priced at $0.35. Each unit includes one common share and one common share purchase warrant. Each warrant entitles the holder to acquire one additional common share, at an exercise price of $0.50. Warrants remain valid for 24 months from the date of closing.
With a market cap (as of this writing) of $45 million, Theralase Technologies still effectively represents a ground-floor opportunity – in relation to the economic potential for success. Not only can investors jump into this ground-floor opportunity as TLT prepares to enter a Phase II clinical study for its lead anti-cancer treatment, they can take advantage of this opportunity with the generous bonus of a full warrant.
Theralase Technologies: help to fund exciting anti-cancer research while providing yourself with an investment that offers enormous potential. The Stockhouse DealRoom: your destination to participate in exclusive financings, featuring some of the best companies – and deals – currently available on the market.
View the Theralase Technologies
DealRoom Private Placement
for full details on their current financing opportunity
FULL DISCLOSURE: Theralase Technologies Inc. is a paid client of Stockhouse Publishing.